AI & Tech · London

Isomorphic Labs raises $5bn in AI drug discovery round led by Sequoia and Greenoaks

Isomorphic Labs, the London-based AI drug discovery company led by Demis Hassabis, announced the round on Tuesday, 17 November. The company did not disclose its valuation, though Bloomberg had reported about $50bn earlier in November.

AI text based on reports by The Telegraph, Handelsblatt, TechCrunch and other publishers. Published . How it is made

For membersThe first 30 seconds for everyone. Synthetic voice (AI).

In brief

London · United Kingdom

A $5bn round led by two growth investors

Isomorphic Labs, the London-based company that uses artificial intelligence to design new medicines, announced on Tuesday, 17 November, that it has raised $5bn in a Series C funding round. Sequoia Capital and Greenoaks co-led the round. Andreessen Horowitz came in as a new investor, while existing backers took part too, among them Alphabet's GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. The company said investors oversubscribed the round.

Valuation and funding history

The company did not disclose its valuation. Bloomberg had reported earlier in November that the round would value Isomorphic at about $50bn. The money follows a $2.1bn Series B in May 2026, only about six months earlier. Across roughly eighteen months the company has raised nearly $8bn, even though it has not yet developed a medicine and has missed timelines it set for itself.

Isomorphic Labs funding rounds in 2026$bn
2026-05
2.1 $bn
2026-11-17
5 $bn

Data from the article text

Pipeline and trial timeline

Isomorphic was spun out of Google DeepMind in 2021 and builds an AI drug-design engine, IsoDDE, that runs many simulation models across chemistry. The company says the engine is producing positive preclinical results in its own oncology and immunology programmes and with partners. More than 20 programmes are under way, and pharma partners include Eli Lilly, Novartis and Johnson & Johnson.

In January, Hassabis said Isomorphic expected its first clinical trials by the end of 2026. He did not give Bloomberg an updated target, but said the company is on track with its regulatory submissions and will have more to announce in 2027. Regulators have not yet approved any drug designed with AI.

Leadership and the platform plan

Hassabis stepped back as chief executive of Google DeepMind in August, during an Alphabet reorganisation. He is now DeepMind's chair and Alphabet's chief scientist, and he remains Isomorphic's chief executive. The new round is the company's first since that change. Hassabis told Bloomberg the money will speed the move toward clinical trials, and that the company will extend beyond small-molecule drugs into large-molecule biologics as well.

Hassabis described the goal in broad terms:

“What we're trying to build is a platform to do hundreds of drugs a year.”

Demis Hassabis, founder and chief executive of Isomorphic Labs

Investor rationale

Sequoia partner Konstantine Buhler framed the investment around the underlying technology.

“Isomorphic Labs is building foundational technology for the future of medicine.”

Konstantine Buhler

Buhler told Bloomberg that Sequoia backed the company because its models have shown scaling laws, meaning performance keeps improving as they receive more computing power and data.

Ask about this text

Sources and context

Places
London

Pollar is free and carries no ads in the text. Its members keep it going.

Support Pollar